Jacqueline K. Barton
Known title: DirectorCIK: 0001183680
Associated companies
Transaction History
| GILD | ▲ Buy | Grant | 1,146 | $0 | 4/30/2026 | View on chart |
| GILD | ▲ Buy | Grant | 1,516 | $0 | 5/7/2025 | View on chart |
| GILD | ▲ Buy | Grant | 2,310 | $0 | 5/8/2024 | View on chart |
| GILD | ▲ Buy | Grant | 1,887 | $0 | 5/3/2023 | View on chart |
| GILD | ▲ Buy | Grant | 2,444 | $0 | 5/5/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,223 | — | 5/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers
Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.